Rein Therapeutics Inc.
RNTX
$1.16
$0.043.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 20.69% | -101.38% | -134.53% | -239.15% | -299.71% |
| Total Depreciation and Amortization | -98.41% | -99.13% | -99.21% | -97.04% | -47.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.69% | 2,658.38% | 3,337.93% | 3,604.55% | 3,113.91% |
| Change in Net Operating Assets | -135.86% | -791.48% | 86.23% | 95.48% | 144.82% |
| Cash from Operations | 13.14% | 24.82% | 17.39% | -13.60% | -12.54% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -87.97% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.84% | -82.01% | -82.01% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10.17% | -50.71% | -54.74% | -- | -- |
| Cash from Financing | -45.25% | -78.13% | -85.30% | 17.49% | 12.81% |
| Foreign Exchange rate Adjustments | -- | 56.45% | 98.39% | 100.00% | 100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.74% | -344.12% | -285.37% | -208.92% | -136.91% |